ClinicalTrials.gg
RecruitingNCT07614984Updated Nov 12, 2026

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

A Phase 2 interventional study of MK-7262 and Enlicitide in Lipoprotein(a), sponsored by Merck Sharp & Dohme LLC. Recruiting at 77 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 12, 2026First site in Colombia23 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C).

The goals of this trial are to evaluate:

  • if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood
  • if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood
  • the safety and tolerability of taking MK-7262 and enlicitide alone and together
02

Conditions studied

  • Lipoprotein(a)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has Lp(a) ≥ 150 nmol/L
  • Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH
  • Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization
  • Has infection, unless the infection is controlled (i.e. undetectable viral load)
  • Has an active virus infection or active or chronic virus infection
  • Has a history of nephrotic syndrome
  • Has severe renal insufficiency
  • Has received certain therapies in the prohibited timeframe as specified in the protocol
  • Has active or chronic hepatobiliary or hepatic disease
  • Has poorly controlled Type 1 or Type 2 diabetes
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
750 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive MK-7262 placebo + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment.

    Drug: Placebo for MK-7262 · Drug: Placebo for enlicitide

  • Active comparator
    enlicitide monotherapy

    Participants will receive enlicitide + MK-7262 placebo orally once daily (QD) for up to approximately 12 weeks of treatment.

    Drug: Enlicitide · Drug: Placebo for MK-7262

  • Experimental
    MK-7262 monotherapy

    Participants will receive MK-7262 + enlicitide placebo orally once daily (QD) for up to approximately 12 weeks of treatment.

    Drug: MK-7262 · Drug: Placebo for enlicitide

  • Experimental
    MK-7262 + enlicitide

    Participants will receive MK-7262 + enlicitide orally once daily (QD) for up to approximately 12 weeks of treatment.

    Drug: MK-7262 · Drug: Enlicitide

Interventions

  • DrugMK-7262

    Oral Coated Tablet

    Also known as: HRS-5346

  • Oral Coated Tablet

    Also known as: MK-0616, enlicitide decanoate

  • DrugPlacebo for MK-7262

    Oral Coated Tablet

  • DrugPlacebo for enlicitide

    Oral Coated Tablet

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Lipoprotein (a) (Lp(a)) at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change from baseline in Lp(a).

    Time frame: Baseline and Week 8

  2. Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C.

    Time frame: Baseline and Week 8

  3. Number of Participants who Experience One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 20 Weeks

  4. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 12 Weeks

Secondary outcomes

  1. Percent Change from Baseline in LDL-C at Week 8 (enlicitide monotherapy vs. placebo)

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C between participants treated with enlicitide monotherapy versus placebo.

    Time frame: Baseline and Week 8

  2. Percent Change from Baseline in LDL-C at Week 8 (MK-7262 monotherapy vs. placebo)

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C between participants treated with MK-7262 monotherapy versus placebo.

    Time frame: Baseline and Week 8

  3. Percent Change from Baseline in Lp(a) at Week 8 (MK-7262 + enlicitide vs. MK-7262 monotherapy)

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in Lp(a) between participants treated with MK-7262 + enlicitide versus MK-7262 monotherapy.

    Time frame: Baseline and Week 8

  4. Percent Change from Baseline in LDL-C at Week 8 (MK-7262 + enlicitide vs. enlicitide monotherapy)

    Blood samples will be collected at baseline and at Week 8 to assess the mean percent change in LDL-C between participants treated with MK-7262 + enlicitide versus enlicitide monotherapy.

    Time frame: Baseline and Week 8

  5. Percentage of Participants with Lp(a) <125 nmol/L at Week 8

    Blood samples will be collected at Week 8 to assess the percentage of participants who have Lp(a) \<125 nmol/L. The percentage of participants with Lp(a) \<125 nmol/L at week 8 will be reported.

    Time frame: Week 8

  6. Percentage of Participants with Lp(a) <75 nmol/L at Week 8

    Blood samples will be collected at Week 8 to assess the percentage of participants who have Lp(a) \<75 nmol/L. The percentage of participants with Lp(a) \<75 nmol/L at week 8 will be reported.

    Time frame: Week 8

  7. Percent Change from Baseline in Lp(a) at Week 12

    Blood samples will be collected at baseline and at Week 12 to assess the mean percent change from baseline in Lp(a).

    Time frame: Baseline and Week 12

  8. Percent Change from Baseline in LDL-C at Week 12

    Blood samples will be collected at baseline and at Week 12 to assess the mean percent change from baseline in LDL-C.

    Time frame: Baseline and Week 12

07

Study locations

77 of 77 sites recruiting
  • Advanced Cardiovascular - Alexander City ( Site 0158)
    Alexander City, Alabama 35010, United States
    Recruiting
    • Study Coordinator · Contact256-215-5323
  • AMR Clinical Mobile ( Site 0149)
    Mobile, Alabama 36608, United States
    Recruiting
    • Study Coordinator · Contact251-414-1984
  • National Heart Institute ( Site 0113)
    Beverly Hills, California 90211-2285, United States
    Recruiting
    • Study Coordinator · Contact310-289-5221
  • Headlands Research CTR Lincoln ( Site 0127)
    Lincoln, California 95648, United States
    Recruiting
    • Study Coordinator · Contact916-434-8230
  • Chase Medical Research, LLC ( Site 0163)
    Waterbury, Connecticut 06708, United States
    Recruiting
    • Study Coordinator · Contact203-419-4420
  • Soffer Health Institute ( Site 0123)
    Hollywood, Florida 33020, United States
    Recruiting
    • Study Coordinator · Contact305-250-2106
  • Westside Center for Clinical Research ( Site 0161)
    Jacksonville, Florida 32205, United States
    Recruiting
    • Study Coordinator · Contact904-693-1490
  • Inpatient Research Clinic ( Site 0110)
    Miami Lakes, Florida 33014, United States
    Recruiting
    • Study Coordinator · Contact786-502-4303
  • Clinical Research Trials of Florida ( Site 0101)
    Tampa, Florida 33607, United States
    Recruiting
    • Study Coordinator · Contact813-873-8102
  • Conquest Research LLC ( Site 0140)
    Winter Park, Florida 32789, United States
    Recruiting
    • Study Coordinator · Contact407-916-0060
  • Flourish Research - Bowie ( Site 0106)
    Bowie, Maryland 20715, United States
    Recruiting
    • Study Coordinator · Contact410-824-1341
  • Velocity Clinical Research Rockville ( Site 0146)
    Rockville, Maryland 20854, United States
    Recruiting
    • Study Coordinator · Contact240-698-2800
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0132)
    Troy, Michigan 48098, United States
    Recruiting
    • Study Coordinator · Contact248-312-0025
  • Minneapolis Heart Institute - Minneapolis ( Site 0130)
    Minneapolis, Minnesota 55407, United States
    Recruiting
    • Study Coordinator · Contact612-863-3833
  • Montana Medical Research, Inc. ( Site 0156)
    Missoula, Montana 59808, United States
    Recruiting
    • Study Coordinator · Contact406-549-1124
  • New Mexico Clinical Research & Osteoporosis Center ( Site 0119)
    Albuquerque, New Mexico 87106, United States
    Recruiting
    • Study Coordinator · Contact505-855-5505
  • Laurelton Heart Specialist PC ( Site 0155)
    Rosedale, New York 11422, United States
    Recruiting
    • Study Coordinator · Contact718-949-9400
  • Velocity Clinical Research, Durham ( Site 0145)
    Durham, North Carolina 27701, United States
    Recruiting
    • Study Coordinator · Contact919-503-4711
  • Remington-Davis, Inc. ( Site 0107)
    Columbus, Ohio 43215, United States
    Recruiting
    • Study Coordinator · Contact614-487-2560
  • Holston Medical Group ( Site 0117)
    Kingsport, Tennessee 37660, United States
    Recruiting
    • Study Coordinator · Contact423-857-2789
  • Center for Cardiometabolic Disease Prevention/Baylor College of Medicine ( Site 0154)
    Houston, Texas 77030, United States
    Recruiting
    • Study Coordinator · Contact713-798-5800
  • DM Clinical Research ( Site 0115)
    Tomball, Texas 77375, United States
    Recruiting
    • Study Coordinator · Contact346-550-9559
  • Carient Heart & Vascular - Manassas ( Site 0165)
    Manassas, Virginia 20109, United States
    Recruiting
    • Study Coordinator · Contact571-581-1771
  • Rainier Clinical Research Center ( Site 0116)
    Renton, Washington 98057, United States
    Recruiting
    • Study Coordinator · Contact425-251-1720
  • North York Diagnostic and Cardiac Centre ( Site 0203)
    North York, Ontario M6B 3H7, Canada
    Recruiting
    • Study Coordinator · Contact416-783-0000
  • Ecogene-21 ( Site 0202)
    Chicoutimi, Quebec G7H 7K9, Canada
    Recruiting
    • Study Coordinator · Contact418-545-1252
  • Clinique des Maladies Lipidiques de Quebec ( Site 0201)
    Québec, Quebec G1V 4W2, Canada
    Recruiting
    • Study Coordinator · Contact418-780-1376
  • Diex Recherche Trois-Rivieres ( Site 0204)
    Trois-Rivières, Quebec G9A 4P3, Canada
    Recruiting
    • Study Coordinator · Contact819-801-9797
  • Salud SURA Industriales ( Site 0405)
    Medellín, Antioquia 05001, Colombia
    Recruiting
    • Study Coordinator · Contact+573193374390
  • Clinica de la Costa S.A.S ( Site 0404)
    Barranquilla, Atlántico 80020, Colombia
    Recruiting
    • Study Coordinator · Contact+57 3128335766
  • Solano & Terront Servicios Medicos - UNIENDO SAS ( Site 0402)
    Bogota, Cundinamarca 110221, Colombia
    Recruiting
    • Study Coordinator · Contact+573016831697
  • IMAT S.A.S ( Site 0400)
    Montería, Departamento de Córdoba 23001, Colombia
    Recruiting
    • Study Coordinator · Contact+57 3017057680
  • Regionshospitalet Viborg ( Site 0507)
    Viborg, Central Jutland 8800, Denmark
    Recruiting
    • Study Coordinator · Contact+4521269495
  • Sanos Clinic - Nordjylland ( Site 0502)
    Gandrup, North Denmark 9362, Denmark
    Recruiting
    • Study Coordinator · Contact+45 73708220
  • Esbjerg sygehus, Syddansk Universitetshospital ( Site 0505)
    Esbjerg, Region Syddanmark 6700, Denmark
    Recruiting
    • Study Coordinator · Contact004579182268
  • OUH Svendborg Sygehus ( Site 0500)
    Svendborg, Region Syddanmark 5700, Denmark
    Recruiting
    • Study Coordinator · Contact+4563202000
  • Klinikum Konstanz ( Site 0723)
    Konstanz, Baden-Wurttemberg 78464, Germany
    Recruiting
    • Study Coordinator · Contact+497538010
  • Hector-Center fuer Ernaehrung ( Site 0715)
    Erlangen, Bavaria 91054, Germany
    Recruiting
    • Study Coordinator · Contact+4991318545220
  • Deutsches Herzzentrum Muenchen ( Site 0717)
    Munich, Bavaria 80636, Germany
    Recruiting
    • Study Coordinator · Contact+498912180
  • Ambulantes Herzzentrum Kassel ( Site 0721)
    Kassel, Hesse 34121, Germany
    Recruiting
    • Study Coordinator · Contact+49561937690
  • Dedicated Research Site FutureMeds ( Site 0719)
    Offenbach, Hesse 63065, Germany
    Recruiting
    • Study Coordinator · Contact+4969247433849
  • Studienzentrum Brinkum - Torsten Drescher & Dr. Lars Pohlmeier ( Site 0712)
    Stuhr, Lower Saxony 28816, Germany
    Recruiting
    • Study Coordinator · Contact+494218305310
  • Universitaetsklinikum Carl Gustav Carus, Technische Universitaet Dresden' ( Site 0713)
    Dresden, Saxony 01307, Germany
    Recruiting
    • Study Coordinator · Contact+4935145811722
  • zibp GmbH ( Site 0716)
    Berlin, 10439, Germany
    Recruiting
    • Study Coordinator · Contact+4930233212880
  • FutureMeds GmbH ( Site 0718)
    Berlin, 10629, Germany
    Recruiting
    • Study Coordinator · Contact+4930439741610
  • Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 0714)
    Berlin, 12203, Germany
    Recruiting
    • Study Coordinator · Contact+493045061847
  • Medical Corporation Heishinkai OCROM Clinic ( Site 2403)
    Suita, Osaka 565-0853, Japan
    Recruiting
    • Study Coordinator · Contact+81-6-6330-8810
  • Kumanomae Nishimura Naika Clinic ( Site 2407)
    Arakawa City, Tokyo 116-0012, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-5855-7555
  • Minamino Cardiovascular Hospital ( Site 2406)
    Hachiōji, Tokyo 192-0918, Japan
    Recruiting
    • Study Coordinator · Contact+81-42-637-8101
  • Kato Clinic of Internal Medicine ( Site 2402)
    Katsushika-ku, Tokyo 125-0054, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-5668-2161
  • Swing Nozaki Clinic ( Site 2405)
    Musashino, Tokyo 180-0022, Japan
    Recruiting
    • Study Coordinator · Contact+81-422-36-3534
  • Medical Corporation Heishinkai ToCROM Clinic ( Site 2404)
    Shinjuku, Tokyo 160-0008, Japan
    Recruiting
    • Study Coordinator · Contact+81-3-5366-5333
  • Medical Corporation Hakuaikai Wellness Tenjin Clinic ( Site 2400)
    Fukuoka, 810-0001, Japan
    Recruiting
    • Study Coordinator · Contact+81-92-738-3335
  • Midori Clinic ( Site 2401)
    Nagasaki, 852-8034, Japan
    Recruiting
    • Study Coordinator · Contact+81-95-844-7191
  • National Hospital Organization Osaka National Hospital ( Site 2408)
    Osaka, 540-0006, Japan
    Recruiting
    • Study Coordinator · Contact+81-6-6942-1331
  • Ziekenhuis Gelderse Vallei ( Site 1106)
    Ede, Gelderland 6716 RP, Netherlands
    Recruiting
    • Study Coordinator · Contact+31318435855
  • Ziekenhuis St. Jansdal ( Site 1113)
    Harderwijk, Gelderland 3844 DG, Netherlands
    Recruiting
    • Study Coordinator · Contact+310341463883
  • Bravis Ziekenhuis, locatie Roosendaal ( Site 1102)
    Roosendaal, North Brabant 4708 AE, Netherlands
    Recruiting
    • Study Coordinator · Contact31887068000
  • Noordwest Ziekenhuisgroep ( Site 1110)
    Alkmaar, North Holland 1815 JD, Netherlands
    Recruiting
    • Study Coordinator · Contact+31725484495
  • Antonius Ziekenhuis, locatie D&A Research and Genetics ( Site 1103)
    Sneek, Provincie Friesland 8601 ZR, Netherlands
    Recruiting
    • Study Coordinator · Contact0515-434275
  • Albert Schweitzer Ziekenhuis, locatie Dordwijk ( Site 1101)
    Dordrecht, South Holland 3318 AT, Netherlands
    Recruiting
    • Study Coordinator · Contact+31786523366
  • Martini Ziekenhuis ( Site 1108)
    Groningen, 9728 NT, Netherlands
    Recruiting
    • Study Coordinator · Contact31505245641
  • Hospital Universitario Nuestra Senora de Valme ( Site 1415)
    Seville, Andalusia 41014, Spain
    Recruiting
    • Study Coordinator · Contact+34955015878
  • Hospital San Rafael - La Coruña ( Site 1402)
    A Coruña, La Coruna 15006, Spain
    Recruiting
    • Study Coordinator · Contact+34655624017
  • Vithas Hospital Sevilla ( Site 1401)
    Castilleja de la Cuesta, Sevilla 41950, Spain
    Recruiting
    • Study Coordinator · Contact+34658011529
  • Hospital Universitari Vall d Hebron ( Site 1403)
    Barcelona, 08035, Spain
    Recruiting
    • Study Coordinator · Contact+34934896134
  • Hospital Clinic de Barcelona ( Site 1419)
    Barcelona, 08036, Spain
    Recruiting
    • Study Coordinator · Contact932279846
  • Hospital Viamed Santa Elena ( Site 1422)
    Madrid, 28003, Spain
    Recruiting
    • Study Coordinator · Contact+34621151370
  • Hospital Universitario La Paz ( Site 1405)
    Madrid, 28046, Spain
    Recruiting
    • Study Coordinator · Contact+34912071427
  • Hospital Universitario Virgen de la Arrixaca ( Site 1406)
    Murcia, 30120, Spain
    Recruiting
    • Study Coordinator · Contact+34968381027
  • Nuevas Tecnologías en D y E - Sevillaocío ( Site 1412)
    Seville, 41003, Spain
    Recruiting
    • Study Coordinator · Contact+34656193053
  • HOSPITAL CLINICO DE VALENCIA ( Site 1407)
    Valencia, 46010, Spain
    Recruiting
    • Study Coordinator · Contact+34961973520
  • University Hospital Basel ( Site 1701)
    Basel, Canton of Basel-City 4031, Switzerland
    Recruiting
    • Study Coordinator · Contact+41613287482
  • HOCH Health Ostschweiz ( Site 1703)
    Sankt Gallen, Canton of St. Gallen 9007, Switzerland
    Recruiting
    • Study Coordinator · Contact41714941228
  • Istituto Cardiocentro Ticino - Ente Ospedaliero Cantonale ( Site 1705)
    Lugano, Canton Ticino 6900, Switzerland
    Recruiting
    • Study Coordinator · Contact+41 91 8115055
  • Hopitaux Universitaires (Geneve) ( Site 1704)
    Geneva, 1211, Switzerland
    Recruiting
    • Study Coordinator · Contact+41223727192
  • Luzerner Kantonsspital ( Site 1702)
    Lucerne, 6000, Switzerland
    Recruiting
    • Study Coordinator · Contact+41412055000
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

6 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
May 29, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Oct 12, 2027
CompletionEst.
Oct 12, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
23 sites added — first site in Colombia
Show 23 added (8 Spain, 4 Colombia, 3 Germany, 2 Denmark, 2 Switzerland, 2 Canada, 1 Japan, 1 Netherlands)
  • Salud SURA Industriales ( Site 0405) · Medellín, Colombia
  • Clinica de la Costa S.A.S ( Site 0404) · Barranquilla, Colombia
  • Solano & Terront Servicios Medicos - UNIENDO SAS ( Site 0402) · Bogota, Colombia
  • OUH Svendborg Sygehus ( Site 0500) · Svendborg, Denmark
  • Universitaetsklinikum Carl Gustav Carus, Technische Universitaet Dresden' ( Site 0713) · Dresden, Germany
  • National Hospital Organization Osaka National Hospital ( Site 2408) · Osaka, Japan
  • Noordwest Ziekenhuisgroep ( Site 1110) · Alkmaar, Netherlands
  • Hospital San Rafael - La Coruña ( Site 1402) · A Coruña, Spain
  • Hospital Universitari Vall d Hebron ( Site 1403) · Barcelona, Spain
  • Hospital Clinic de Barcelona ( Site 1419) · Barcelona, Spain
  • Hospital Viamed Santa Elena ( Site 1422) · Madrid, Spain
  • Hospital Universitario La Paz ( Site 1405) · Madrid, Spain
  • IMAT S.A.S ( Site 0400) · Montería, Colombia
  • Esbjerg sygehus, Syddansk Universitetshospital ( Site 0505) · Esbjerg, Denmark
  • Deutsches Herzzentrum Muenchen ( Site 0717) · Munich, Germany
  • University Hospital Basel ( Site 1701) · Basel, Switzerland
  • Ecogene-21 ( Site 0202) · Chicoutimi, Canada
  • Diex Recherche Trois-Rivieres ( Site 0204) · Trois-Rivières, Canada
  • Hospital Universitario Virgen de la Arrixaca ( Site 1406) · Murcia, Spain
  • Istituto Cardiocentro Ticino - Ente Ospedaliero Cantonale ( Site 1705) · Lugano, Switzerland
  • Hospital Universitario Nuestra Senora de Valme ( Site 1415) · Seville, Spain
  • Hector-Center fuer Ernaehrung ( Site 0715) · Erlangen, Germany
  • HOSPITAL CLINICO DE VALENCIA ( Site 1407) · Valencia, Spain
across 6 updates, Sep 28, 2026 – Nov 12, 2026
Show all 6 updates
  1. Nov 12, 2026
    1 site added
    Show site
    • HOSPITAL CLINICO DE VALENCIA ( Site 1407) · Valencia, Spain
    + 1 other change: verification date
  2. Oct 23, 2026
    1 site added
    Show site
    • Hector-Center fuer Ernaehrung ( Site 0715) · Erlangen, Germany
  3. Oct 20, 2026
    1 site added
    Show site
    • Hospital Universitario Nuestra Senora de Valme ( Site 1415) · Seville, Spain
  4. Oct 13, 2026
    4 sites added
    Show 4 added (2 Canada, 1 Spain, 1 Switzerland)
    • Ecogene-21 ( Site 0202) · Chicoutimi, Canada
    • Diex Recherche Trois-Rivieres ( Site 0204) · Trois-Rivières, Canada
    • Hospital Universitario Virgen de la Arrixaca ( Site 1406) · Murcia, Spain
    • Istituto Cardiocentro Ticino - Ente Ospedaliero Cantonale ( Site 1705) · Lugano, Switzerland
    + 1 other change: verification date
  5. Oct 1, 2026
    4 sites added
    Show 4 added (1 Colombia, 1 Denmark, 1 Germany, 1 Switzerland)
    • IMAT S.A.S ( Site 0400) · Montería, Colombia
    • Esbjerg sygehus, Syddansk Universitetshospital ( Site 0505) · Esbjerg, Denmark
    • Deutsches Herzzentrum Muenchen ( Site 0717) · Munich, Germany
    • University Hospital Basel ( Site 1701) · Basel, Switzerland
  6. Sep 28, 2026
    12 sites added — first site in Colombia
    Show 12 added (5 Spain, 3 Colombia, 1 Denmark, 1 Germany, 1 Japan, 1 Netherlands)
    • Salud SURA Industriales ( Site 0405) · Medellín, Colombia
    • Clinica de la Costa S.A.S ( Site 0404) · Barranquilla, Colombia
    • Solano & Terront Servicios Medicos - UNIENDO SAS ( Site 0402) · Bogota, Colombia
    • OUH Svendborg Sygehus ( Site 0500) · Svendborg, Denmark
    • Universitaetsklinikum Carl Gustav Carus, Technische Universitaet Dresden' ( Site 0713) · Dresden, Germany
    • National Hospital Organization Osaka National Hospital ( Site 2408) · Osaka, Japan
    • Noordwest Ziekenhuisgroep ( Site 1110) · Alkmaar, Netherlands
    • Hospital San Rafael - La Coruña ( Site 1402) · A Coruña, Spain
    • Hospital Universitari Vall d Hebron ( Site 1403) · Barcelona, Spain
    • Hospital Clinic de Barcelona ( Site 1419) · Barcelona, Spain
    • Hospital Viamed Santa Elena ( Site 1422) · Madrid, Spain
    • Hospital Universitario La Paz ( Site 1405) · Madrid, Spain

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07614984
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Jun 30, 2026
Primary completion
Oct 12, 2027 (estimated)
Completion
Oct 12, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enlicitide

Start the discussion